By Sheeba M. | April 16, 2026
Canopy Growth Reports Q4 2025 Earnings: What Retail Investors Need to Know
The Numbers at a Glance
Canopy Growth Corporation (NASDAQ: CGC) reported fourth quarter fiscal 2025 results this week, posting net revenue of approximately $95 million CAD — roughly flat compared to the same period last year. The topline stagnation comes as no surprise given the ongoing challenges in the Canadian recreational market, where price compression has been a persistent headwind.
Adjusted EBITDA losses narrowed to $12 million CAD from $19 million a year ago, signaling operational discipline even as revenue growth stalls. Gross margins held steady at 23%, in line with recent quarters.
What German Legalization Means for Canopy
The real story for sophisticated investors is Canopy’s international positioning. The company has quietly built one of the most extensive European distribution footprints among North American cannabis operators, anchored by its partnership with Schonheiser GmbH in Germany.
Germany’s landmark cannabis reform, which took effect in March 2024, has created a legal medical cannabis market that analysts estimate could reach €7 billion annually at maturity. Canopy Growth is among the handful of Canadian LPs with existing regulatory approvals to ship product directly — a structural advantage that won’t be easy to replicate.
2026 Guidance: The Bull Case
Management guided to mid-single-digit revenue growth in fiscal 2026, with EBITDA breakeven targeted by Q3. This assumes continued strength in Canadian medical sales and meaningful contribution from European exports — a bet on regulatory tailwinds that are trending favorably.
Skeptics will note that CGC has missed or low-balled guidance before. Bulls counter that this time the company has actual international revenue contracts in hand, not just pipeline promises.
Bottom Line
Canopy Growth is not a turnaround story in the traditional sense — it has real revenue, real operations, and real international exposure. The question is whether European momentum can offset Canadian headwinds before the next equity raise. For investors with a 12-18 month horizon, CGC warrants a position on the watch list. Aggressive entry below $2.50 CAD offers the best risk-reward given the Germany catalyst.
Sources
- Canopy Growth Official Investor Relations — Q4 2025 earnings press release and financial statements
- Bloomberg — German medical cannabis market size estimates and regulatory coverage
- SEC Filings — CGC annual report and proxy statements
Track cannabis stocks with the Weedstock Real-Time Tracker